Disruption of p53 in human cancer cells alters the responses to therapeutic agents.
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
We have examined the effects of commonly used chemotherapeutic agents on human colon cancer cell lines in which the p53 pathway has been specifically disrupted by targeted homologous recombination. We found that p53 had profound effects on drug responses, and these effects varied dramatically depending on the drug. The p53-deficient cells were sensitized to the effects of DNA-damaging agents as a result of the failure to induce expression of the cyclin-dependent kinase inhibitor p21. In contrast, p53 disruption rendered cells strikingly resistant to the effects of the antimetabolite 5-fluorouracil (5-FU), the mainstay of adjuvant therapy for colorectal cancer. The effects on 5-FU sensitivity were observed both in vitro and in vivo, were independent of p21, and appeared to be the result of perturbations in RNA, rather than DNA, metabolism. These results have significant implications for future efforts to maximize therapeutic efficacy in patients with defined genetic alterations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Some conventional chemotherapeutic drugs depend on the activation of p53 for their efficacy.”
From CDK4 inhibition diminishes p53 activation by MDM2 antagonists (2018) · cites this paper as [44]
The cited source says what the claim attributes to it.
In the citing paper
“Comparing p53-proficient and -deficient HCT116 cells, such a dependency was found in particular for 5-fluorouracil (5-FU)44.”
From CDK4 inhibition diminishes p53 activation by MDM2 antagonists (2018) · cites this paper as [44]
In the citing paper
“A series of clinical studies have confirmed that CRC patients with wild-type P53 can benefit from 5-FU, and CRC patients with mutant P53 have a poor prognosis when receiving adjuvant chemotherapy [258,259,260].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [259]
In the citing paper
“A series of clinical studies have confirmed that CRC patients with wild-type P53 can benefit from 5-FU, and CRC patients with mutant P53 have a poor prognosis when receiving adjuvant chemotherapy [258,259,260].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [259]
In the citing paper
“On the other hand, the same report showed that p53-deficient cells displayed a higher sensitivity towards topoisomerase inhibitors such as Adriamycin.”
From CDK4 inhibition diminishes p53 activation by MDM2 antagonists (2018) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Green, D. R., & Reed, J. C. (1998) · Science · doi:10.1126/science.281.5381.1309 · Cited by 8,965
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803 · cited 4×
“We attribute this difference to the small amount of p53independent p21 induction following DNA damage that occurs after adriamycin treatment of p53-deficient cells (not shown), similar to that observed after γ-irradiation (14).”
BackgroundMethodInfluentialSelf-citationA model for p53-induced apoptosis
Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/38525 · Cited by 2,500
Self-citationKo, L. J., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.9.1054 · Cited by 2,344 · cited 1×
“Introduction The p53 gene is inactivated in the majority of human cancers, resulting in profound effects on cell birth and death processes (1, 2).”
BackgroundMice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
p53 Status and the Efficacy of Cancer Therapy in Vivo
Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., & Jacks, T. (1994) · Science · doi:10.1126/science.7973635 · Cited by 1,469 · cited 1×
“with mouse cells, for example, have provided unequivocal evidence of drug resistance after p53 inactivation (9, 10), but the extrapolation of these results to humans is far from straightforward.”
BackgroundApoptosis in cancer therapy: Crossing the threshold
Fisher, D. E. (1994) · Cell · doi:10.1016/0092-8674(94)90518-5 · Cited by 1,315
Is a p53-Regulated Inhibitor of G2/M Progression
Hermeking, H., Lengauer, C., Polyak, K., He, T.-C., Zhang, L., Thiagalingam, S., Kinzler, K. W., & Vogelstein, B. (1997) · Molecular Cell · doi:10.1016/s1097-2765(00)80002-7 · Cited by 1,251 · cited 1×
“The checkpoint function of p53 is mediated by the genes it transcriptionally regulates, including p21 (14, 15, 16) and 14-3-3σ (28), and keeps cells from progressing from G1 to S or G2 to M after DNA damage.”
BackgroundSelf-citationRadiation-induced cell cycle arrest compromised by p21 deficiency
Brugarolas, J., Chandrasekaran, C., Gordon, J. I., Beach, D., Jacks, T., & Hannon, G. J. (1995) · Nature · doi:10.1038/377552a0 · Cited by 1,242
O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., et al. (1997) · PubMed · Cited by 867
Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21
Waldman, T., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1996) · Nature · doi:10.1038/381713a0 · Cited by 728
Self-citationTelomerase activation by the E6 gene product of human papillomavirus type 16
Klingelhutz, A. J., Foster, S. A., & McDougall, J. K. (1996) · Nature · doi:10.1038/380079a0 · Cited by 660 · cited 1×
“Similarly, the use of human papilloma virus–derived E6 to inactivate p53 (10) has complicated the interpretation of experiments on drug sensitivity, because E6 has major effects on cells other than just those mediated by p53 inhibition (12).”
BackgroundReactive oxygen species are downstream mediators of p53-dependent apoptosis.
Johnson, T. M., Yu, Z. X., Ferrans, V. J., Lowenstein, R. A., & Finkel, T. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11848 · Cited by 596
p53 In tumour pathology: Can we trust immunohistochemistry?—revisited!
Hall, P. A., & Lane, D. P. (1994) · The Journal of Pathology · doi:10.1002/path.1711720103 · Cited by 561 · cited 1×
“While some clinical studies have been encouraging with respect to the ability to predict responses based on p53 genotype (5–7), such studies are often confounded by tumor variability and technical difficulties in reliably assessing p53 inactivation in naturally occurring tumors (8).”
BackgroundMetabolism and mechanism of action of 5-fluorouracil
Parker, W. B., & Cheng, Y. C. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90056-8 · Cited by 451 · cited 2×
“Additionally, 5-FU has been shown to be misincorporated into both DNA and RNA, with consequent effects on the structure and function of these nucleic acids (20, 21).”
BackgroundBlandino, G., Levine, A. J., & Oren, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202314 · Cited by 441
Cell-cycle arrest versus cell death in cancer therapy
Waldman, T., Zhang, Y., Dillehay, L., Yu, J., Kinzler, K., Vogelstein, B., & Williams, J. (1997) · Nature Medicine · doi:10.1038/nm0997-1034 · Cited by 389 · cited 2×
“The checkpoint function of p53 is mediated by the genes it transcriptionally regulates, including p21 (14, 15, 16) and 14-3-3σ (28), and keeps cells from progressing from G1 to S or G2 to M after DNA damage.”
BackgroundMethodSelf-citationVayssiere, J. L., Petit, P. X., Risler, Y., & Mignotte, B. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.24.11752 · Cited by 311
Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents.
Hawkins, D. S., Demers, G. W., & Galloway, D. A. (1996) · PubMed · Cited by 297
Wyllie, A. (1997) · PubMed · Cited by 224
Predicting response to cancer chemotherapy: the role of p53
Weller, M. (1998) · Cell and Tissue Research · doi:10.1007/s004410051072 · Cited by 222
Pritchard, D. M., Watson, A. J. M., Potten, C. S., Jackman, A. L., & Hickman, J. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.1795 · Cited by 198 · cited 2×
“It has been shown that p53 deficiency leads to increased resistance to 5-FU in mice (26).”
BackgroundLowe, S. W. (1995) · Current Opinion in ONCOLOGY · doi:10.1097/00001622-199511000-00013 · Cited by 194
Benhattar, J., Cerottini, J.-P., Saraga, E., Metthez, G., & Givel, J.-C. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960621)69:3<190::aid-ijc7>3.0.co;2-v · Cited by 100
Ren, Z.-P., Pontén, F., Nistér, M., & Pontén, I. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960621)69:3<174::aid-ijc4>3.0.co;2-x · Cited by 96
Gene Targeting in Human Cells Without Isogenic DNA
Sedivy, J. M., Vogelstein, B., Liber, H. L., Hendrickson, E. A., & Rosmarin, A. G. (1999) · Science · doi:10.1126/science.283.5398.9a · Cited by 73 · cited 1×
“Recent technological advances have allowed the successful targeting of individual genes in human somatic cell lines and the identification and isolation of the desired homologous recombinants (13).”
BackgroundSelf-citationEffect of 5-fluorouracil on RNA metabolism in Novikoff hepatoma cells.
Cory, J. G., Breland, J. C., & Carter, G. L. (1979) · PubMed · Cited by 72
Luna‐Pérez, P., Arriola, E. L., Cuadra, Y., Alvarado, I., & Quintero, A. (1998) · Annals of Surgical Oncology · doi:10.1007/bf02303772 · Cited by 45
Drug Resistance and its Clinical Circumvention
Moscow, J. A., Cowan, K. H., & Sikic, B. I. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm063 · Cited by 44
Brett, M. C., Pickard, M. R., Green, B., Howel-Evans, A. W., Smith, D. B., Kinsella, A. R., & Poston, G. J. (1996) · European Journal of Surgical Oncology · doi:10.1016/s0748-7983(96)90827-6 · Cited by 41
Enhanced cytotoxicity with interleukin-1 alpha and 5-fluorouracil in HCT116 colon cancer cells.
Geoffroy, F., Allegra, C. J., Sinha, B. K., & Grem, J. L. (1994) · PubMed · Cited by 40
Which guesstimate is the best guesstimate? Predicting chemotherapeutic outcomes
Lamb, J. R., & Friend, S. H. (1997) · Nature Medicine · doi:10.1038/nm0997-962 · Cited by 26 · cited 1×
“These results emphasize the difficulties in extrapolating from in vitro assays to in vivo situations and suggest that apoptosis may, in some cases, be a better predictor of drug responsiveness in vivo than colony formation (33).”
(1995) · PubMed
Self-citation
Research works printed but not linked: 6
- Hawkins, 1996, Cancer Res, 56, 892
- O’Connor, 1997, Cancer Res, 57, 4285
- Waldman, 1995, Cancer Res, 55, 5187
- Geoffroy, 1994, Oncol Res, 6, 581
- Wyllie, 1997, Eur J Cell Biol, 73, 189
- Cory, 1979, Cancer Res, 39, 4905
Cited by
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332
“In vitro studies have reported that loss of p53 function reduces cellular sensitivity to 5-F”
Johnstone (2002) · doi:10.1016/s0092-8674(02)00625-6 · Cited by 1,876
Death and anti-death: tumour resistance to apoptosis
Igney, F. H., & Krammer, P. H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc776 · Cited by 2,075
Lowe, S. W., & Lin, A. W. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.485 · Cited by 1,876
Molecular mechanisms of drug resistance
Longley, D., & Johnston, P. (2005) · The Journal of Pathology · doi:10.1002/path.1706 · Cited by 1,672
“For example, in vitro studies have reported that loss of p53 function reduces chemosensitivity to 5-FU [49,121].”
Background
Metadata
- Authors
- Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B.
- Affiliations
- Howard Hughes Medical Institute (US)
- Georgetown University (US)
- Johns Hopkins University (US)
- Corresponding author
- Vogelstein, Bert
- Venue
- Journal of Clinical Investigation
- Published
- 1999-08-01
- Volume
- 104
- Issue
- 3
- Pages
- 263-269
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC408422
- OpenAlex
- W1982097971
- Cited by
- 1,044
- References
- 33
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 17 · 2023: 26 · 2022: 23 · 2021: 19 · 2020: 27 · 2019: 26 · 2018: 25 · 2017: 24 · 2016: 36 · 2015: 32 · 2014: 35 · 2013: 43 · 2012: 38
- FWCI
- 22.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Foundation for Cancer Research
- Johns Hopkins University
- National Institutes of Health
- National Cancer Institute (CA 57345, R01CA057345, P50CA062924, R37CA057345, CA 62924)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- p53, p53 deficiency, chemoresistance, 5-fluorouracil, antimetabolite resistance, p21, cyclin-dependent kinase inhibitors, DNA-damaging agents, chemosensitization, colon cancer, colorectal cancer, RNA metabolism, drug response
- MeSH terms
- Animals, Antineoplastic Agents, Colonic Neoplasms, DNA Damage, Doxorubicin, Fluorouracil, Humans, Mice, Nude, Neoplasm Transplantation, Transplantation, Heterologous, Tumor Cells, Cultured, Genes, p53, Tumor Suppressor Protein p53, Cyclins, Apoptosis, Gene Deletion, Drug Resistance, Neoplasm, Cyclin-Dependent Kinase Inhibitor p21, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.